Join the Psoriatic Arthritis group to help and get support from people like you.
Psoriatic Arthritis News
Psoriatic Arthritis Tied to Delays in Diagnosis Compared With Rheumatoid Arthritis
WEDNESDAY, April 30, 2025 – Patients with psoriatic arthritis (PsA) have delays in diagnosis compared with those with rheumatoid arthritis (RA), according to a study published online March 29 in...
Psoriatic Arthritis Diagnoses Are Lagging, Patients Undertreated
FRIDAY, April 18, 2025 – It’s taking too long for people with psoriatic arthritis to be diagnosed and treated, a new study argues. Visible signs of psoriatic arthritis appear months and even years b...
FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
JERSEY CITY, N.J., Dec. 17, 2024 – Celltrion announced today that the U.S. Food and Drug Administration (FDA) has approved Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for...
FDA Approves Yesintek (ustekinumab-kfce), a Biosimilar to Stelara
Bengaluru, Karnataka, India, December 01, 2024 -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced ...
American College of Rheumatology, Nov. 14-19
The annual meeting of the American College of Rheumatology was held this year from Nov. 14 to 19 in Washington, D.C., and attendees included rheumatology specialists, physicians, scientists, and o...
FDA Approves Imuldosa (ustekinumab-srlf), a Biosimilar to Stelara
RALEIGH, N.C., Oct. 14, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...
FDA Approves Otulfi (ustekinumab-aauz), a Biosimilar to Stelara
September 30, 2024 – Fresenius Kabi, an operating company of Fresenius, specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs for critical and chronic...
UCB announces U.S. FDA approvals for Bimzelx (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis
Brussels (Belgium), September 23, 2024 – 07:00 (CEST) – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Bimzelx (bi...
FDA Approves Bimzelx for Three New Indications
THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Bimzelx (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active n...
Psoriasis, Psoriatic Arthritis Tied to Higher Risk of Polyneuropathy
MONDAY, July 29, 2024 – Psoriasis and psoriatic arthritis may be associated with an increased risk of polyneuropathy, according to a study published online June 28 in Muscle & Nerve. Pietro E. ...
Psoriasis, With or Without Psoriatic Arthritis, Associated With Fatigue
MONDAY, July 1, 2024 – Psoriasis is associated with fatigue, especially among those with psoriatic arthritis (PsA), according to a study published in the July issue of the Journal of the American...
FDA Expands Pediatric Indication for Rinvoq
FRIDAY, June 21, 2024 – The U.S. Food and Drug Administration has expanded indications for Rinvoq (upadacitinib) to now include pediatric patients (ages 2 years and older) with polyarticular...
FDA Approves Selarsdi (ustekinumab-aekn), a Biosimilar to Stelara
REYKJAVIK, Iceland & PARSIPPANY, N.J.--(BUSINESS WIRE) April 16, 2024 --Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
FDA Approves Simlandi (adalimumab-ryvk), an Interchangeable Biosimilar to Humira
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE:...
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 – Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory...
Further information
Related condition support groups
Related drug support groups
prednisone, methotrexate, Humira, triamcinolone, cortisone, Enbrel, Stelara, Remicade, Xeljanz, view more... Otezla, Cosentyx, Skyrizi, dexamethasone, adalimumab, etanercept, ustekinumab, Cimzia, Taltz